Presence and impact of antidrug antibodies (adas) to tremelimumab (t) or durvalumab (d) in the phase 3 himalaya study of unresectable hepatocellular carcinoma (uhcc).
Publication date:
2023
Descripción física:
p. 551-551
Patrocinado por:
AstraZeneca